C urrently, more than a quarter of the female adult world population and 3-fold more of postmenopausal women in the United Sates have arterial hypertension.
1,2 Sex differences in blood pressure (BP) and rate of hypertension play an important role in the susceptibility to cardiovascular disease. [2] [3] [4] [5] Moreover, hypertension is often undiagnosed or inadequately controlled in women, especially after menopause when cardiovascular risk increases. 6 Endogenous estrogens are held to contribute to the maintenance of normal BP in premenopausal women, who show lower BP values than age-matched men. 3 Estrogens elicit direct vasodilatory effects in vivo, albeit they may affect BP also through other mechanisms, including inhibition of sympathetic tone. 3 During the menstrual cycle, BP is inversely related with circulating estrogen concentrations and is lower when 17β-estradiol (E2) levels peak. 7 After menopause, both vascular aging, which leads to arterial stiffening, and the cessation of endogenous estrogen production contribute to a raise in BP, 2, 6 thereby increasing the risk of hypertension, atherosclerotic vascular disease, myocardial infarction, and stroke. 2, 6, 8 Hormone replacement therapy can alleviate the postmenopausal BP increase and can reduce coronary vascular risk and carotid artery subclinical atherosclerosis progression, [9] [10] [11] [12] [13] [14] but this protective effect is lost in women who are many years after menopause. 2, 6 The effects of estrogens on other potent pressor mechanisms, and particularly those involving the renin-angiotensin-aldosterone system (RAAS), have received less attention as discussed below. Likely, this can explain why mineralocorticoid receptor antagonists, which entail an effective treatment of resistant/refractory arterial hypertension, 15, 16 are still underused in postmenopausal women, 17 notwithstanding the high rate of resistant hypertension in this population. 
Estrogens and the RAAS
Aldosterone, one of the major effectors of the RAAS, is a major contributor to cardiovascular mortality in patients with heart failure. [18] [19] [20] [21] Moreover, its inappropriately high levels raise BP in overweight-obese patients with hypertension, 22 and in patients with primary aldosteronism, 23 the most common form of endocrine hypertension. 24 Compared with BP-matched essential hypertensive patients, 25, 26 these latter patients develop more severe target organ damage 27 and are at higher cardiovascular risk. Identification of the molecular mechanisms underpinning the excess production of aldosterone, and the role of estrogens in this context, can thus be of much interest for improving strategies to combat hypertension and the resulting cardiovascular disease.
The RAAS is known to be regulated by estrogens 28, 29 : contraceptive formulations or orally administered postmenopausal hormone therapy increase the renin substrate (angiotensinogen) in plasma through hepatic induction. 29 Estrogens also stimulate renin release from the juxtaglomerular cells through estrogen receptor-α (ERα), 30 whereas endogenous estrogens exert inhibitory effects on the RAAS. 28, 29 Experimental studies have shown that circulating levels of aldosterone increase after menopause and that estrogen therapy blunts this increase [31] [32] [33] [34] [35] ; however, corresponding data in humans are lacking.
Data on the effects of estrogens on aldosterone synthesis in the adrenocortical zona glomerulosa (ZG) are scarce, but the detection of binding sites for estrogens and progesterone in the adrenal 36 suggests a modulatory role of these hormones in aldosterone synthesis, possibly through interactions with secretagogues as angiotensin II, serum K + , adrenocorticotropic hormone, and other vasoactive factors, including endothelin-1 and urotensin II. [37] [38] [39] Estrogens can freely diffuse into the nucleus and therefore were initially thought to act exclusively via the nuclear ERα (esr1) and ERβ (esr2). 40 This concept changed when, in 1999, membrane subpopulations of ERα and ERβ were identified and also rapid intracellular signaling of estrogens via the 7-transmembrane G-protein-coupled estrogen receptor-1 (GPER-1) was reported. 41, 42 The subsequent demonstration that E2 affects aldosterone synthesis and release 40, 42, 43 opened a novel exciting chapter of the aldosterone saga. Hence, we will herein review the distribution pattern of ERs in the adrenal cortex, their role in the regulation of aldosterone synthesis, and the implications of the most recent discoveries in this field. For clarity purposes, estradiol, 2 the physiologically most relevant estrogen, is referred throughout the text as E2, whereas the term estrogens refer to estrogens and their derivatives.
ERα and ERβ
Two nuclear ER subtypes, ERα and ERβ, have been identified and cloned in 1986 [44] [45] [46] and 1996, 47, 48 respectively. Notwithstanding their relatively low (59%) sequence identity in the ligand-binding domains, they exhibit similar binding affinity and specificity for estrogens. 49 After binding E2 in the cytoplasm, and forming homo-or heterodimers, the ERs translocate to the nucleus where, by interacting with estrogen response elements, they modulate expression of peroxisome proliferator activator γ, endothelial nitric oxide synthase, connexin, and heat shock proteins genes ( Figure  S1 in the online-only Data Supplement). [50] [51] [52] [53] [54] The receptor homo-or heterodimers affect gene expression also indirectly via transcription factor or via ligand-independent mechanisms involving a growth factor that induces phosphorylation of ER. 55 Membrane subpopulations of ERs deriving from the same transcripts yielding nuclear ERs, which anchor to plasma membrane lipids, 56 have been implicated in the rapid (nongenomic) estrogen signaling. 57, 58 ERα induces rapid activation of NO synthase transcription, phosphorylation of serine residues, nitric oxide production, and also endothelial cell angiogenesis and regeneration, 59 whereas ERβ mediates vasodilation via endothelium-dependent hyperpolarization. 60 The nongenomic effects of E2 on endothelial cells involve protein caveolin-1, mitogen-activated protein kinases, and PI 3 /Akt leading to increases in intracellular Ca 2+ concentrations.
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For expression and tissue-specific functions of ERs, please refer to Table. Functions of ER-related receptors are discussed in the Data Supplement.
GPER-1
In the 1990s, a novel membrane bound G protein-coupled receptor was independently cloned in 6 laboratories [72] [73] [74] [75] [76] [77] and assigned different names. 72, 73 It initially received the orphan receptor designation GPR30 and was identified as a membrane protein mediating the rapid effects of E2. 40, 42, 43, 78 Because of its high homology with other protein receptors, the natural ligand of GPR30 was suspected to be a peptide, although none among all screened peptides provoked any detectable response in GPR30-transfected cells. 40, 42, 43 81 GPER-1 was found to be located at the plasma membrane, the endoplasmic reticulum, and Golgi, at variance with the classic ERs that were detected in the cytoplasm and, on binding E2, in the nucleus. 40, 42, 43 E2 binding to GPER-1, but not to ERα or ERβ, induces synthesis of phosphatidylinositol 3,4,5-triphosphate and intracellular Ca 2+ mobilization, 41 which were abolished by the epithelial growth factor receptor inhibitor AG1478, 41 indicating that the estrogen-triggered Ca 2+ mobilization involves GPER-1 via epithelial growth factor receptor transactivation. 40, 42, 43 Independent studies 82, 83 were unable to detect any binding of aldosterone to GPER-1-containing membrane fractions; therefore, currently there is no evidence that would support the notion that GPER-1 can also act as an aldosterone receptor. 84, 85 However, the available data suggest that GPER-1 can interact with the nuclear mineralocorticoid receptor by receptor cross talk, 42, 85, 86 (as it  does with ERα  87 and ERβ   88 ), which is also suggested in aldosterone-dependent renal cancer metastasis. 89 Xenoextrogens, phytoextrogens, selective estrogen receptor modulators, selective estrogen receptor downregulators (SERDs), and catecholestrogens can also bind to GPER-1. 40, 90 Whether the same holds true for 7β-hydroxy-epiandrosterone, a metabolite of dehydroxy-epiandrosterone, remains to be confirmed at present. 91 The identification of synthetic small molecules that act as a GPER-1-selective agonist (G1), and antagonist (G15 and G36), has shed some light in this field. 40, 42, 43 Akin to E2, G1 stimulates the rapid Ca 2+ currents in a kidney fibroblast COS-7 cell line expressing green fluorescent protein-tagged GPER-1.
It is currently unclear whether circulating free concentrations of E2 are sufficient to exert binding to ERs and whether these concentrations exert significant biological effects under nonpregnant conditions. However, the local (tissue) formation of E2 through α-aromatase has been demonstrated in the adrenal 92 and the arterial vasculature, suggesting that the E2 concentrations can be sufficient to act locally. 88, 93 Because aromatase inhibition abrogates the salutary of E2, 88, 93 paracrine E2-mediated actions are likely to play a significant biological role. Measurements of E2 tissue concentrations using microdialysis, however, are still lacking.
Subcellular Localization of GPER-1
Initially localized to the endoplasmic reticulum and found to traffic to the Golgi apparatus, 41 ,94 the GPER-1 was, thereafter, found to shuttle dynamically to and from the plasma membrane through vesicular (endosomes) transport. [95] [96] [97] This trafficking forms the basis for GPER-1 desensitization (through endocytosis), resensitization (through recycling to plasma membrane), and down-regulation (through proteolytic degradation). 98, 99 On interaction with its ligand(s), GPER-1 undergoes conformational changes that result in the dissociation of Gα from Gβγ subunit, leading to the intracellular activation of phosphoinositide-3-kinase, with ensuing increase of cAMP and intracellular Ca 2+ . 95, 100 The latter increases mitochondrial Ca 2+ , resulting in Ca 2+ -dependent mitochondrial cAMP production and enhanced aldosterone secretion. 101 GPER-1-mediated signaling also occurs via recruitment of β-arrestin and change of integrins affinity for extracellular matrix proteins, 95 a process known as inside-out integrin signaling, which could be crucial for cell proliferation, and tumor development. 95 Therefore, ERs interact in several ways differing from those initially conceived, indicating that the picture is far more complex than originally thought.
Expression of ERs in the Normal Adrenal Gland
The first evidence of estrogen binding in the adrenal cortex was found in rodents in 1978, 102 ERα and ERβ were then detected in the adrenal cortex of rhesus monkeys, 103 at higher levels in the adult than in the fetal adrenal gland, with no sex differences. 103 In humans, studies of ERs expression in the fetus, which is exposed to high estrogen levels, 104, 105 from the 20th to the 38th gestational week, in the definitive zone of the adrenal cortex showed higher levels of ERβ than ERα mRNA. 104 The predominant ERβ expression was confirmed in
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2001, but found to be more abundant in the cortisol-producing definitive zone, and absent in the fetal zone. 92 In the postnatal human adrenals, the expression and localization of ERα and ERβ remained unknown until 2007 when in relatively large number of normal adrenal glands the expression of ERβ was reported to change with time from birth to adolescence. Expression decreased at the age of 3 months, when the fetal zone undergoes physiological involution, and increased with adrenarche (at a mean age of 6 years), when the fully developed zona reticularis starts to produce the androgen precursor dehydroepiandrosterone and its sulfate ester, dehydroepiandrosterone sulfate. 106 By contrast, ERα remains undetectable until childhood and puberty. 106 Of note, ERβ immunostaining in the zona reticularis was found in both the cytoplasm and the nucleus. Expression of GPER-1 protein in the adrenal gland, with prominent expression levels in the ZG and the medulla from adrenarche to puberty, was first reported in humans in 2007. 106, 107 In adults, the expression of ERs remained unknown until 2008, when 2 groups independently reported high expression of ERβ and low expression of ERα. 92, 108 However, the expression of GPER-1 remained unknown until 2014 when we first detected GPER-1, besides the classic ERs and the recently identified ERα isoform ERα36, in the human adult adrenal cortex. 69 By different techniques, we found the more abundantly expressed receptor to be the ERβ, which showed prominent nuclear and cytoplasmic location. 69 The expression of the ERα and its variant ERα36 was scant, with only occasional nuclear immunostaining in the ZG ( Figure S2 ). 69 The immunostaining for GPER-1, albeit strong in the ZG, was appreciable also in the zona fasciculata and reticularis, both in the plasma membrane and in the cytoplasm. 69 
Expression Pattern of ERs in Neoplasms of the Adrenal Cortex
In 2008, 3 groups independently reported the expression of ERα and ERβ in adrenocortical tumors with higher levels of ERβ than ERα transcript. 92, 108, 109 In 2009, a pregnant woman with aldosterone-producing adenoma (APA) was described to have a predominant expression of ERβ, suggesting a similar expression pattern of ERs in these tumors and in the normal adrenal gland. 110 At variance, by systematically examining both GPER-1 and ERα36 expressions in APA, we found markedly different ER mRNA levels between tumors and the normal gland: the GPER-1 prevailed in the former, ERβ in the latter tissue, whereas both ERα and ERα36 were scarcely expressed ( Figure S2) . 69 CD56 + aldosterone-producing cells isolated from APAs also exhibited GPER-1 higher expression than ERβ and ERα, supporting the view that GPER-1 predominates in the aldosterone-producing cells. 69 Thus, albeit with profound differences both normal and tumorous adrenocortical tissues express ERα, ERβ, and GPER-1. 71, 92, 108, 111 Whether these receptors play any role in cell growth and adrenal neoplasms development and spread remains unknown. 71 
Estrogen Modulation of Aldosterone Synthesis
The adrenocortical carcinoma cell line HAC15 can be used as a model to investigate the effect of E2 on aldosterone production because they express all ER subtypes. 69 In these cells, E2 alone, or in conjunction with an ERα antagonist, does not affect CYP11B2 expression. However, when administered in addition to the ERβ antagonist (R,R)-5,11-diethyl-5,6,11,12-tetrahydro-2,8-chrysenediol (THC), it causes a 2.5-fold increase in CYP11B2 gene expression, indicating a tonic inhibitory effect of E2 via ERβ on CYP11B2 transcription. Removal of this inhibition unveils a secretagogue effect of E2 on aldosterone production that occurs via GPER-1 ( Figure) . 69 This was confirmed by experiments with the selective GPER-1 agonist G-1, alone or combined with 1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy) phenol]-1H-pyrazole dihydrochloride (MPP), or THC, or both. 69 When given in the presence of an ERβ antagonist, G1 markedly increases both CYP11B2 mRNA, and aldosterone levels in the supernatant. 69 Moreover, pretreatment with the selective GPER-1 antagonist G-15 abrogated the increase of CYP11B2 gene expression and aldosterone secretion induced by either E2 or G1 during inhibition of ERα and ERβ. 69 G-15 also abolished the E2-induced aldosterone secretion that occurred during combined ERα and ERβ blockade.
In HAC15 cells, GPER-1 gene silencing of reduced CYP11B2 mRNA and protein expression by 53% and 72%, respectively, whereas, conversely, ERβ silencing increased CYP11B2 mRNA and protein expression by 62% and 93%, respectively, and aldosterone production by 17%, when compared with mock-transfected cells. 69 Neither the ERβ-dependent inhibitory effect nor the GPER-1-mediated stimulatory effect of E2 on aldosterone involve [Ca 2+ ] I cell uptake because exposure of HAC15 cells to E 2 alone, or in the presence of the antagonists (THC, or MPP+THC), elicited no changes in [Ca 2+ ] I currents. By contrast, the increase of CYP11B2 expression induced by either E2 or G-1, during combined ERα and ERβ blockade, in HAC15 cells was abolished by a specific PKA inhibitor. 69 Hence, collectively these results evidenced that GPER-1-mediated E 2 -induced aldosterone production occurs via protein kinase A-cAMP signaling. The discovery of the opposing effects of GPER-1 and ERβ on adrenal aldosterone synthesis might explain why estrogens, alone or combined with angiotensin II, elicited no effects on aldosterone secretion in the absence of ERβ antagonists. 112 It can, therefore, be concluded that: (1) estrogens physiologically inhibit aldosterone synthesis by activating ERβ receptors; (2) when these receptors are antagonized, or their expression changes (as in APA tissue), E2 becomes a potent aldosterone secretagogue via GPER-1 (Table; Figure) . 69 
Figure.
Mechanisms of 17β-estradiol (E2)-dependent regulation of the gene transcription of aldosterone synthase (CYP11B2) in the normal adrenal gland and the aldosterone-producing adenoma (APA). A, In the normal adrenal gland, the estrogen receptor β (ERβ), which is the predominant ER in the adrenal cortex, after binding to E2, dimerizes leading to the formation of an active estrogen-ER complex. The complex binds to estrogen response elements (ERE), thereby blunting gene transcriptions of CYP11B2. Given that G protein-coupled estrogen receptor-1 (GPER-1) is expressed at a lower level, GPER-1-mediated effects are negligible. B, In the APA, E2 mostly binds to GPER-1, which is the most abundant receptor subtype in the APA. GPER-1, via cross-talk with ERβ, promotes aldosterone synthesis thereby preventing the tonic inhibitory effect of ERβ on CYP11B2. The mechanisms depicted in A and B may explain why menopause increases circulating aldosterone levels in experimental studies and the inhibitory effect of estrogen therapy on aldosterone levels. These mechanism may also contribute to the high prevalence of hypertension among postmenopausal women and explain how higher estrogen levels in premenopausal women could blunt aldosterone production via the ERβ subtype, whereas the cessation of E2 production after menopause would abolish such inhibition.
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ERs and Adrenal Cell Proliferation
A proliferative effect of estrogens was first evidenced on adrenal cells in 2003 113 and confirmed in 2005 by thymidine incorporation studies. 70 Using H295R cells to generate xenograft tumors in athymic (nude) mice in which they silenced the ERs, Sirianni et al 68 showed that E2-induced proliferation involves mainly the ERα and downstream the activation of cyclin D1 expression, although an E2 (ligand)-independent activation was also discovered. 68, 70 Phosphorylation of serine 118 and 167 of the ERα, or of AKT, or activation of IGF-1 (insulin growth factor-1) receptor also promoted H295R cell proliferation. 68 By contrast, GPER-1 was involved in cell apoptosis: G1-induced arrest of H295R cell cycle at the G2 phase leading to DNA damage and death (Table) . 71 Whether upregulation of GPER-1 underpins inhibition of tumor growth in APA remains to be clarified.
The fetal definitive zone of the adrenal gland contains tightly packed cells with a proliferative phenotype that persists throughout gestation and acquires mineralocorticoid synthesis capacity only in late gestation. 114 The subscapsular portion of this zone and the adult ZG exhibits the highest immunostaining for Ki-67, a marker of cell proliferation, which is paralleled by GPER-1 staining. 114 These findings, alongside the evidence of ERβ-mediated H295R cell proliferation, 70 suggest that estrogens stimulate the outer subcapsular zone adrenal progenitor cell proliferation and migration by acting via ERβ or GPER-1.
Adrenocortical ERs and Primary Aldosteronism
The different expression pattern of ERs between APA and normal adrenal cortex, 69, 92, 106, 108 along with the capability of E2 to enhance aldosterone production via GPER-1 during ERβ blockade, 69 suggests cross-talk between GPER-1 and ERβ in the development of high BP and primary aldosteronism. In line with this proposition, it was found that E2 decreases aldosterone levels and the response of aldosterone to angiotensin II in ovariectomized female rats. 33, 34 Although the expression of ERβ and GPER-1 was not investigated, it could be that E2 inhibits the GPER-1-mediated secretagogue effect of E2. Moreover, ovariectomy was associated with increased BP, long-term mortality, and plasma aldosterone; the latter was prevented by E2 or phytoestrogens. 31 Further studies with selective GPER-1 antagonists, or agonists, as opposed to the nonselective agonist E2, are, therefore, necessary to gain further light on the role of 3 ER subtypes in this context.
A Possible Link Between Adrenal ERs and Sex Differences in BP
Compared with age-matched men, premenopausal women are largely protected from high BP and cardiovascular disease, a protection that wanes after menopause along with the cessation of ovarian estrogen production. 2, 3, 7 Evidence exists for a BP-lowering and cardiovascular risk-lowering role of estrogens via their salutary effects on sympathetic activation, salt handling, endothelium-dependent vascular function, and the RAAS. 28, 29 The expression of the ERs in the adrenocortical ZG and the functional evidence that the activation of CYP11B2 occurs when the ERβ subtype receptor is antagonized, collectively suggest an involvement of aldosterone via ER-related mechanism in the sex differences of hypertension: in premenopausal women high estrogen levels could blunt aldosterone production, and thereby onset of hypertension, via the ERβ subtype; conversely, the fall of E2 after menopause could abolish this inhibition. The aforementioned animal studies support this contention. 31, 33 Whether the density of GPER-1 or its affinity for E2, and the related pathways, change with age and postmenopause remains to be determined, but it is worth noting that E2 itself regulates ER expression. 52, [115] [116] [117] Thus, higher estrogen levels in premenopausal women and loss of estrogen in postmenopausal women can affect the expression and the relative amount of ERα, ERβ, and GPER-1 in the adrenal cortex.
ER-Related Effects in Women Treated With SERMs
SERMs are approved for the treatment of the most common female cancer worldwide and the second most frequent cause of cancer death in women, 118 for example, ER-positive breast cancer, and for ovarian cancers. 118 In the United States, the expected number of new cases of these cancers within the current year is about a quarter million accounting for 29% of all cancers. 119 Of all breast cancer, ≈80% express ER and receive SERMs therapy, which means that many women are currently receiving treatment with SERMs because of ER-positive malignancies, although how these drugs affect the regulation of adrenocortical hormone production is unknown. For the reasons discussed above, it is possible that the protective effects of E2-related ERβ-mediated inhibition of aldosterone are reduced in women treated with SERMs or SERDs. In fact, SERMs, such as raloxifene and the active metabolite of tamoxifen, 4-hydroxy-tamoxifen, as well as the SERDs faslodex/fulvestrant act as GPER-1 agonists. 4, 40 Moreover, both SERMs and SERDs bind to ERα and ERβ, thus exerting estrogenic effects in some tissue and the opposite in others. 120 Hence, when combined with ERβ antagonist(s), GPER-1 agonist(s) can increase aldosterone production with an ensuing pressor effect. However, whether SERMs or SERDs adversely affected cardiovascular risk via an enhanced adrenal aldosterone production is unknown, but the likelihood might be small because women receiving SERMs or SERDs do not seem to develop hypertension, perhaps because of the increased NO bioactivity and reduced oxidative stress induced by these drugs. [121] [122] [123] The fact that arterial hypotension, likely because of arterial vasodilation, 63 entails a known side effect of faslodex/fulvestrant therapy in women diagnosed with breast cancer supports this contention.
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Conclusions
The adrenal cortex expresses all ER subtypes: ERα and its isoform ERα36, ERβ, and GPER-1, but ERβ shows the highest expression in the ZG. 64, 69 By contrast, GPER-1 predominates in APAs, which suggests a role for this receptor in primary aldosteronism. 69 Estrogens tonically inhibit aldosterone synthesis by acting on ERβ, 88 and, therefore, could physiologically lower its levels in premenopausal women. This could also, in part, explain why hormone replacement therapy reduces BP in postmenopausal women. 2, 7 The waning of this ERβ-mediated inhibition, in conjunction with the finding that estrogens potently activate aldosterone production by acting via GPER-1, 69 might well contribute to the high prevalence of resistant/salt-sensitive hypertension among postmenopausal women. 2, 7 Adrenal estrogen signaling may, thus, substantially account for the sex differences in BP and postmenopausal incidence and prevalence of hypertension. 1 Figure S1 . Non-genomic and genomic estrogen signaling. Endogenous estrogen 17β-estradiol (E 2 ) acts as a nonselective activator of the three known estrogen receptors (ERs), ERα, ERβ, and GPER. For genomic signaling, 17β-Estradiol activates nuclear ERs, resulting in receptor dimerization and binding of receptor dimers to promoters of target genes. Alternatively, activated ERs modulate the function of other classes of transcription factors (TF) through protein-protein interactions. Subpopulations of ERs at the plasma membrane are activated by E 2 and interact with adaptor proteins (adaptor) and signaling molecules such as c-Src, which mediates rapid signaling via PI3K-Akt and MAPK pathways. E 2 and the selective agonists (G-1), or the selective estrogen receptor down regulators (SERDs, fulvestrant), or selective estrogen receptor modulators (SERMs, tamoxifen) also activate GPER. In the endoplasmic reticulum GPER stimulates cAMP production, Ca 2+ mobilization and c-Src, which activate
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Sources of Funding
MMPs. MPPs cleave pro-HB-EGF, releasing free HB-EGF that trans-activates EGFR that, in turn, activates MAPK and PI3K-Akt pathways with additional rapid (non-genomic) effects (X), or genomic effects. E 2 -mediated transcriptional regulation involves phosphorylation (P) of ER or other TFs that may directly interact with ER, or bind independently of ER within the promoters of target genes. Abbreviations: Akt, serine/threonine kinase Akt / protein kinase B; E 2 , 17β-estradiol; EGFR, epidermal growth factor receptor; ER, estrogen receptor; GPER, G protein-coupled ER; MAPK, mitogen-activated protein kinase; MMP, matrix metalloproteinase; PI3K, phosphoinositide 3-kinase; pro-HB-EGF, pro-heparin-binding-epidermal growth factor; TF, transcription factor. 
